Cancer drug not fully confirmed for Alzheimer's treatment

05/2013

Last year, a cancer drug, Bexarotene, was touted as a potential treatment for Alzheimer’s disease. However, four independent studies have now failed to replicate the most dramatic result of the original study: a claim that the drug could clear half the amyloid plaques in a mere 72 hours.

Still, two of the studies confirmed findings that the drug reduced levels of amyloid-beta, and one showed improved cognition in mice.

The inconsistencies suggest more research is needed. The drug is now being tested in humans.

http://www.nature.com/news/studies-cast-doubt-on-cancer-drug-as-alzheimer-s-treatment-1.13058

[3435] Shen, H.
(2013).  Studies cast doubt on cancer drug as Alzheimer's treatment.
Nature.

Related News

A study (“Midlife in the United States”) assessing 3,343 men and women aged 32-84 (mean age 56), of whom almost 40% had at least a 4-year college degree, has found evidence that frequent cognitive activity can counteract the detrimental effect of poor education on age-related cognitive decline.

Previous research has shown that older adults are more likely to incorrectly repeat an action in situations where a

It’s now well established that older brains tend to find it harder to filter out irrelevant information. But now a new study suggests that that isn’t all bad.

A study involving 155 women aged 65-75 has found that those who participated in resistance training once or twice weekly for a year significantly improved their selective attention (maintaining mental focus) and conflict resolution (as well as muscular function of course!), compared to those who

A number of rodent studies have shown that blueberries can improve aging memory; now for the first time, a human study provides evidence.

A study involving 57 cognitively healthy older adults has found that those who showed decreased memory performance two years later (20 of the 57) had higher baseline levels of phosphorylated tau231 in the

Midlife hypertension has been confirmed as a risk factor for the development of dementia in late life, but there have been conflicting findings about the role of late-life hypertension.

By following 597 Alzheimer’s patients over 15 years, researchers have determined that a simple progression rate can be calculated at the initial visit, using symptom onset and present performance, and that this can reliably identify slow, intermediate and rapid progression.

A survey of more than 100 studies involving PIB-PET, a diagnostic tool that involves injecting a radiotracer called

Pages

Subscribe to Latest newsSubscribe to Latest newsSubscribe to Latest health newsSubscribe to Latest news